After the IDH mutation status was confirmed to be related to the prognosis of patients with GBMs, a subsequent study reported that the chromosome 1p/19q codeletion status, O6-methylguanine-DNA methyltransferase (MGMT) promoter region genotype, a-thalassemiamental retardation syndrome X (ATRX), and amplification of the epidermal growth factor receptor (EGFR) played more important roles in the prognosis and treatment prediction of gliomas (39, 40). Here, IDH1 is linked to central nervous system cancer.